PMID- 10595741
OWN - NLM
STAT- MEDLINE
DCOM- 20000104
LR  - 20201212
IS  - 0910-5050 (Print)
IS  - 1876-4673 (Electronic)
IS  - 0910-5050 (Linking)
VI  - 90
IP  - 10
DP  - 1999 Oct
TI  - Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic 
      dendritic cells following autologous peripheral blood stem cell transplantation.
PG  - 1117-29
AB  - Dendritic cells (DCs) are believed to be the most potent antigen-presenting cells 
      and may be important in the induction of anti-leukemia specific T cell responses. 
      In this preliminary clinical study, a patient with chronic phase chronic 
      myelogenous leukemia (CML) was vaccinated with autologous leukemic DCs following 
      autologous peripheral blood stem cell transplantation (PBSCT). In an in vitro 
      study, leukemic DCs were generated using granulocyte-macrophage 
      colony-stimulating factor (GM-CSF), tumor necrosis factor-alpha, and 
      interleukin-4 from granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC 
      fraction of this patient, and were found to be Ph1+, and to possess the 
      morphologic and phenotypic characteristics of mature DCs. These cells could also 
      elicit antigen specific immune responses, including a vigorous cytotoxicity 
      specific to CML cells. In the clinical experiment, we obtained evidence that 
      infused leukemic DCs could induce T cell clones expressing the same T cell 
      receptor usage as a cytotoxic T cell line, suggesting that the immune repertoire 
      includes tumor-reactive T cells. These cytotoxic T lymphocytes are activated in 
      vivo. The vaccination of leukemic DC caused a decrease in the number of Ph1+ 
      cells in the peripheral blood and bone marrow. These results indicate that the 
      activity is an immunologically mediated phenomenon and vaccination therapy with 
      leukemic DC following autologous PBSCT may be effective in treating CML.
FAU - Fujii, S
AU  - Fujii S
AD  - The Center for Bone Marrow Transplantation and Immunotherapy, Institute for 
      Clinical Research, Kumamoto National Hospital, Ninomaru. fujii1018@aol.com
FAU - Shimizu, K
AU  - Shimizu K
FAU - Fujimoto, K
AU  - Fujimoto K
FAU - Kiyokawa, T
AU  - Kiyokawa T
FAU - Shimomura, T
AU  - Shimomura T
FAU - Kinoshita, M
AU  - Kinoshita M
FAU - Kawano, F
AU  - Kawano F
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Jpn J Cancer Res
JT  - Japanese journal of cancer research : Gann
JID - 8509412
RN  - 0 (Cancer Vaccines)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
SB  - IM
MH  - Amino Acid Sequence
MH  - *Cancer Vaccines
MH  - Cells, Cultured
MH  - Chromosomes, Human, Pair 22
MH  - Chromosomes, Human, Pair 9
MH  - Combined Modality Therapy
MH  - Dendritic Cells/immunology/*transplantation
MH  - Female
MH  - Flow Cytometry
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Hypersensitivity, Delayed
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/*immunology/*therapy
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Philadelphia Chromosome
MH  - Receptors, Antigen, T-Cell, alpha-beta/chemistry/genetics
MH  - Translocation, Genetic
MH  - Transplantation, Autologous
PMC - PMC5925998
EDAT- 1999/12/14 00:00
MHDA- 1999/12/14 00:01
PMCR- 1999/10/01
CRDT- 1999/12/14 00:00
PHST- 1999/12/14 00:00 [pubmed]
PHST- 1999/12/14 00:01 [medline]
PHST- 1999/12/14 00:00 [entrez]
PHST- 1999/10/01 00:00 [pmc-release]
AID - S091050509980177X [pii]
AID - CAE1117 [pii]
AID - 10.1111/j.1349-7006.1999.tb00686.x [doi]
PST - ppublish
SO  - Jpn J Cancer Res. 1999 Oct;90(10):1117-29. doi: 
      10.1111/j.1349-7006.1999.tb00686.x.